Table 1.
Patient and transplantation characteristics.
| AlloBMTs n=785 | |
|---|---|
| Age, median (range) | 52 (18-75) |
| Male sex, n (%) | 448 (57%) |
| Diagnosis, n (%) | |
| Acute myeloid leukemia or myelodysplastic syndrome | 308 (39%) |
| Mature B-cell neoplasm | 236 (30%) |
| Acute lymphoblastic leukemia | 69 (9%) |
| Myeloproliferative neoplasm, including CML | 52 (7%) |
| Hodgkin lymphoma | 48 (6%) |
| Mature T-cell or NK-cell neoplasm | 36 (5%) |
| Hemoglobinopathy or thalassemia | 17 (2%) |
| Aplastic anemia or paroxysmal nocturnal hemoglobinuria | 9 (1%) |
| Bilineage leukemia | 7 (1%) |
| Histiocytic or dendritic cell neoplasm | 2 |
| Lymphomatoid granulomatosis | 1 |
| Conditioning regimen, n (%) | |
| Reduced-intensity | 456 (58%) |
| Myeloablative | 329 (42%) |
| ATG-containing conditioning regimen, n (%) | 14 (2%) |
| Donor, n (%) | |
| HLA-haploidenticala | 396 (50%) |
| HLA-matched, related | 259 (33%) |
| HLA-matched or 1 antigen mismatched, unrelated | 130 (17%) |
| Allograft source, n (%) | |
| Marrow, T-cell replete | 748 (95%) |
| Peripheral blood, T-cell replete | 37 (5%) |
| GVHD prophylaxis, n (%) | |
| PTCy alone | 313 (40%) |
| PTCy on days +3 and +4 | 302 |
| PTCy on day +3 | 11 |
| PTCy on days +3 and +4/MMF/tacrolimusb | 382 (49%) |
| PTCy on days +3 and +4/MMFc | 55 (7%) |
| PTCy on day +3/MMF/tacrolimusd | 20 (2%) |
| PTCy on days +3 and +4/MMF/sirolimuse | 15 (2%) |
| Rituximab ≤ 12 months after alloBMT, n (%) | 63 (8%) |
| HLA-haploidentical | 55/396 (14%) |
| HLA-matched, related | 8/259 (3%) |
| HLA-matched or 1 antigen mismatched, unrelated | 0/130 |
| DLI ≤ 12 months after alloBMT, n (%) | 57 (7%) |
| HLA-haploidentical | 13/396 (3%) |
| HLA-matched, related | 41/259 (16%) |
| HLA-matched or 1 antigen mismatched, unrelated | 3/130 (2%) |
Abbreviations: alloBMT, allogeneic blood or marrow transplantation; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; NK, natural killer; ATG, anti-thymocyte globulin; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; PTCy, posttransplantation cyclophosphamide; MMF, mycophenolate mofetil; DLI, donor lymphocyte infusion
395 related donors, 1 unrelated donor
MMF 15 mg/kg, 3 times daily up to 1000 mg/dose on days 5-35 and tacrolimus (goal trough 5-15 ng/mL) on days 5-180. Twenty patients received MMF 15 mg/kg twice daily on days 4-33.
MMF 15 mg/kg, twice daily on days 4-33
MMF 15 mg/kg twice daily on days 4-35, tacrolimus (goal trough 5-15 ng/mL) on days 4-50 (n=10) or days 4-180 (n=10)
MMF 15 mg/kg, 3 times daily up to 1000 mg/dose on days 5-35 and sirolimus daily (goal trough 5-15 ng/mL) on days 5-365